Beyond hepatology, MASH is a systemic condition involving liver-related issues (such as fibrosis, cirrhosis, liver failure, hepatocellular carcinoma, and liver transplantation), metabolic complications (like type 2 diabetes), and extrahepatic consequences (including cardiovascular disease, chronic kidney disease, and extrahepatic cancers) [38]
Consistent yoga practice has been shown to improve overall GI motility in multiple clinical studies
In a 2026 podcast interview, Huberman called retatrutide "the peptide that's going to change everything" and described it as a triple agonist of GLP-1, glucagon, and GIP receptors
When I bought it, I could swear it was sold with a link to a lab certification and lot number to verify purity
The first few weeks In our experience, the change patients describe first is usually sleep